Steroid hormone receptor interacting protein kinase
US6673586B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Jan 19, 2001 |
| Grant date | Jan 6, 2004 |
| Priority date | — |
| Expiry date | Jan 19, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N9/1205
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention features a novel p21-activated kinase that interacts with steroid hormone receptors, the steroid hormone receptor interacting p21-activated kinase (PAKSI). In general, the invention provides methods of inhibiting hormone related cancers. More particularly, the present invention relates to inhibiting prostate cancer and breast cancer. The present invention further provides methods of activating the therapeutic effects of steroid hormone receptors, particularly the estrogen receptor. Alternatively, the present invention provides methods of diagnosing steroid hormone receptor-related diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.